PAPERPACK S.A.

😨 Study exposes high cost of pharmacies printing medical information leaflets 😨 🔍 Our newly released study addresses a critical question left unresolved in the proposed Directive: the enormous total cost implications of implementing PoD leaflets alongside electronic Product Information (ePI). With the European Commission's proposal allowing countries to decide on the format of medical leaflets, MLPS underscores the necessity of understanding the financial implications of this decision. 💸💼 📊 The study's findings provide stakeholders with valuable insights into the economic impacts of PoD leaflets. The estimated total cost of PoD leaflets across Europe-27 ranges from €1.680 billion to €3.495 billion annually, depending on whether leaflets are printed in black or four-color ink. This cost impact is 2 to 3 times larger than the current total cost for medical information leaflets. It is crucial to understand who will bear these costs, which are currently borne by the pharma industry. 💰📑 🗣️ "In our commitment to patient safety and accessibility to crucial medical information, it’s imperative to thoroughly understand the financial implications surrounding a proposed legislative change such as removing paper leaflets," stated Mike Turner, Managing Director of MLPS. "This study underscores the need for a comprehensive consideration of all factors involved in the transition to the digitalisation of leaflets and print-on-demand formats; we hope the report will enable an understanding of the implications of PoD to pharmacists, pharmacies and patients." 📚💡 👵 The report highlights how the older population will be disproportionately affected by the removal of paper leaflets, as over 50% of dosages are consumed by people aged over 65. Therefore, PoD will still result in a significant number of paper leaflets being requested by patients. 📰👴 🌍 MLPS emphasizes the need to address the impact of PoD starting with its financial aspect, raising questions about how different Member States will implement PoD in practice, and who will bear these costs. Let's ensure patient safety and accessibility while navigating this transition! 💪💊 Read more about this and find the study on our website: https://lnkd.in/e96ACUfU

🚨 Reminder: Urgent Call for Patient Safety — Preserve Paper Leaflets in Medicinal Packaging! 💊 MLPS (Medical Leaflet = Patient Safety) stresses ongoing concerns about European Commission's proposed Pharmaceutical Directive. Article 63 allows member states to choose between paper leaflets and digital leaflets (ePI) for medicines. 1️⃣ Accessibility for All: The proposed ePI risks excluding millions without digital access. Retaining paper leaflets is essential for equal access to vital medical information. 2️⃣ Print on Demand Challenges: 'Print on Demand' (POD) may lead to inaccuracies and increased costs. We advocate for the removal of POD as a viable alternative to paper leaflets. 3️⃣ Language Needs in Smaller Member States: A complementary approach ensures accessibility, with collaboration addressing language requirements in smaller Member States. 4️⃣ Offline Access for Privacy: Patient data security is paramount. Patients should have the option for offline access to protect their privacy. 📣 Join Our Cause: Let's ensure access to vital medical information for all citizens. Share your thoughts and spread the word. 🌐💊 #PatientSafety #MLPS #HealthAccess #HealthEquity #DigitalHealth 🌐 Learn more about MLPS: https://lnkd.in/euapkMAR